 Drug Therapy Protocols: Glyceryl trinitrate

Disclaimer and copyright
©2018 Queensland Government

All rights reserved. Without limiting the reservation of copyright, no person shall reproduce, store in a retrieval system or transmit in any form, or by any means, part or the whole of the Queensland Ambulance Service (‘QAS’) Clinical practice manual (‘CPM’) without the prior written permission of the Commissioner.

The QAS accepts no responsibility for any modification, redistribution or use of the CPM or any part thereof. The CPM is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents.

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome, please forward to:
Clinical.Guidelines@ambulance.qld.gov.au

<table>
<thead>
<tr>
<th>Date</th>
<th>April, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to Glyceryl trinitrate administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all QAS clinical staff.</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>April, 2021</td>
</tr>
<tr>
<td>Information security</td>
<td>This document has been security classified using the Queensland Government Information Security Classification Framework (QGISCF) as UNCLASSIFIED and will be managed according to the requirements of the QGISF.</td>
</tr>
</tbody>
</table>

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
**Drug class**
Vasodilator

**Pharmacology**
Glyceryl trinitrate (GTN) is a potent vasodilator that decreases preload by increasing venous capacity, pooling venous blood in the peripheral veins, reducing ventricular filling pressure and decreasing arterial blood pressure (after load). Because of this cascade it also causes vasodilation in coronary arteries that are in spasm and may assist the redistribution of blood flow along the collateral channels in the heart.[1–3]

**Metabolism**
GTN is readily absorbed and metabolised by the liver.[1]

---

### Indications

- **Suspected ACS** (with pain)
- **Acute cardiogenic pulmonary oedema**
- **Autonomic dysreflexia**
  (with a systolic BP ≥ 160 mmHg)[4–5]
- **Irukandji syndrome**
  (with a systolic BP ≥ 160 mmHg)

---

### Contraindications

- Allergy and/or Adverse Drug Reaction
- Heart rate < 50 OR > 150 beats per minute
- Systolic BP < 100 mmHg
- Acute CVA
- Head trauma
- Phosphodiesterase inhibitor medication administration (e.g. Viagra® or Levitra®) in the previous 24 hours[6]

---

### Precautions

- Suspected inferior AMI
- Cerebral vascular disease
- Risk of hypotension and/or syncope
- Intoxication (GTN effects are enhanced)
- Phosphodiesterase inhibitor medication administration (e.g. Viagra® or Levitra®) in the previous 4 days

---

### Side effects

- Dizziness
- Hypotension
- Syncope
- Reflex tachycardia
- Vascular headaches
Glyceryl trinitrate

Presentation

- Spray (sublingual), 400 microg/dose, 200 doses, nitrolingual pump spray
- Ampoule, 50 mg/10 mL glyceryl trinitrate

Onset

Duration

Half-life

< 2 minutes 20–30 minutes 5.5 minutes

Schedule

- SUBLING spray – S3 (Therapeutic poisons).
- Ampoule, 50 mg/10 mL – S4 (Restricted drugs).

Routes of administration

Sublingual (SUBLING)

Intravenous infusion (IV INF)

Special notes\(^{[1-4]}\)

- Sublingual GTN is the first line treatment for ACS, however IV GTN should be considered as part of the management regime for all patients unresponsive to sublingual GTN, narcotics and/or β blockers.
- Research has identified that GTN potency may be reduced due to the migration of GTN into certain administration sets. IV INF doses should be titrated according to patient response despite the container and giving set used.
- Prepared GTN IV infusion solutions are stable in polypropylene syringes for 24 hours.
- Some patients with normal or low left ventricular filling pressures or pulmonary capillary pressure may be hypersensitive to the effects of GTN and may respond to IV infusion doses from 5 microg/min.
- CCP ESoP aeromedical officers are to display extreme caution when ceasing GTN infusions due to the potential of rebound symptoms.
- GTN is the first line treatment for autonomic dysreflexia, however morphine should be considered as part of the management regime, if the patient is unresponsive to initial treatment.
- 50 mg/10 mL GTN ampoules are not currently supplied by the QAS warehouse – for procurement information please refer to the QAS Drug Management Code of Practice.
- All cannulae and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.
## Adult dosages

### Suspected ACS (with pain)

<table>
<thead>
<tr>
<th>SUBLING</th>
<th>400 microg</th>
<th>Repeated at 5 minute intervals. No maximum dose.</th>
</tr>
</thead>
</table>

CCP ESoP aeromedical
– RSQ Clinical Coordinator consultation and approval required in all situations. Commence infusion at 10 microg/minute (1 mL/hour) and increase by 10–20 microg/minute (1–2 mL/hour) every 3–5 minutes.

**Syringe preparation:** Mix 30 mg (6 mL) of GTN with 44 mL of glucose 5% in a 50 mL syringe to achieve a final concentration of 600 microg/mL. Ensure all syringes are appropriately labelled. Administer via syringe driver.

If at anytime the patient becomes unresponsive or hypotensive, cease infusion immediately.

Infusion may be recommenced at 50% the preceding dose when patient is GCS 15 and systolic BP > 100 mmHg.

### Acute cardiogenic pulmonary oedema

<table>
<thead>
<tr>
<th>SUBLING</th>
<th>400 microg</th>
<th>Repeated at 5 minute intervals. No maximum dose.</th>
</tr>
</thead>
</table>

### Adult dosages (cont.)

- **Autonomic dysreflexia** (with a systolic BP ≥ 160 mmHg)
- **Irukandji syndrome** (with a systolic BP ≥ 160 mmHg)

<table>
<thead>
<tr>
<th>SUBLING</th>
<th>400 microg</th>
<th>Repeated at 5 minute intervals. No maximum dose.</th>
</tr>
</thead>
</table>

### Paediatric dosages

- **Autonomic dysreflexia** (with a systolic BP ≥ 160 mmHg)
- **Irukandji syndrome** (with a systolic BP ≥ 160 mmHg)

QAS Clinical Consultation and Advice Line approval required in all situations.

**Note:** In all other instances, QAS officers are NOT authorised to administer GTN to paediatric patients.